Mutation Linked to Liver Cancer Treatment Resistance
Researchers identified a specific genetic mutation that hinders immune responses to common liver cancer therapies.
Updated on Oct. 11, 2026 in Cancer
Scientists have linked CTNNB1 mutations to treatment resistance in patients with hepatocellular carcinoma (HCC). This discovery explains why some patients fail to respond to the combination of lenvatinib and anti-PD1 immunotherapy.
Why it matters
Identifying this resistance mechanism could lead to new strategies for enhancing immunotherapy effectiveness in patients with advanced liver cancer. Improving these treatment pathways is vital for overcoming the current limitations faced by non-responding patients.
Researchers analyzed pretreatment biopsies from 78 advanced HCC patients and compared findings with 114 NCC-HCC and 358 TCGA-LIHC samples. Findings suggest that CTNNB1 mutations disrupt immune cell infiltration and maturation.
The players
CTNNB1
A gene often mutated in various cancers that regulates the Wnt signaling pathway and cellular immune responses.
The details
CTNNB1 mutations involving the β-TrCP binding motif suppress tumor-intrinsic NF-κB activity, which normally signals the body to produce inflammatory cytokines. Without these signals, the tumor microenvironment cannot recruit and mature mononuclear phagocytes, leaving the cancer undetected by the immune system. The study found that potentiating this NF-κB activity using E7386 could help restore the effectiveness of anti-PD1 and lenvatinib treatments in these resistant tumor models.
Timeline
October 11, 2026: The research findings were published.
Health Landscape
This research builds upon existing genomic insights from the TCGA-LIHC project to map how specific mutations interfere with the standard of care for liver cancer. It highlights a critical shift toward precision oncology, where identifying resistance mutations may soon dictate the choice of combination therapies.
For patients undergoing immunotherapy for hepatocellular carcinoma, understanding the role of specific tumor mutations is a complex but important topic to discuss with an oncologist. Clinical trials exploring ways to overcome treatment resistance are an essential conversation to have with your care team.
The takeaway
Genetic mutations can prevent the immune system from identifying and fighting liver tumors. Patients or their caregivers should consult their oncology team regarding whether genetic testing or clinical trials targeting treatment-resistant pathways are relevant to their specific diagnosis.
Further reading
For more on the current research landscape, visit our Cancer section.
Source note: This article includes information reported by Nature.
